

Biomark's Collaborator Receives Funding to Validate Its Biomarker Panel for the Early Detection of Lung Cancer

Vancouver, British Columbia--(Newsfile Corp. - March 16, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its sponsored research collaboration with The Metabolomics Innovation Centre (TMIC) was successful in receiving funding from the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition. This comes after the organizers of the competition, the Canadian Cancer Society/Canadian Institutes of Health Research - Institute of Cancer Research, and Brain Canada Foundation, evaluated the full proposal for its relevance to funding opportunities in the prevention and early detection of cancer. The funding application is entitled "A novel rapid, liquid biopsy early-stage lung cancer diagnostic test". The grant was for \$150,000.

The study is being led by Professor David Wishart and his team at The Metabolomics Innovation Centre from the Departments of Biological Sciences and Computing Science at the University of Alberta. The funding will be used to validate BioMark's liquid biopsy platform and proprietary biomarker panel for the detection of early-stage lung cancer in over 1200 patients. Our team, which consists of leaders in oncology, lung cancer, mass spectrometry and clinical translation will work together to ensure the successful translation, implementation, and commercialization of this metabolomics assay. Upon completion of this project, we expect to have: 1) a validated biomarker panel for the detection of early-stage lung cancer; 2) a laboratory-developed test that is compatible and easily integrated on mass spectrometry platforms already routinely used in clinical labs and 3) a well-developed plan for translation and implementation of the test using a proprietary system in an accredited lab in Quebec and later across Canada.

"We are delighted to continue our collaboration with Dr. Wishart and his team at TMIC. Over the past 4 years we have worked hard to establish metabolite biomarkers that are specific to lung cancer in plasma samples and now we begin the final stretch in validating our test toward commercialization across Canada. A simpler, cheaper and more accurate test for early detection of lung cancer would benefit patients by providing improved outcome to high-risk patients. Such a test will also have the potential to disrupt the management of patient at higher risk due to smoking and other environmental exposures, leading to better screening modalities and reduced healthcare burden globally," Mr. Bux added.

About Sparks Grant.

BioMark would like to thank The Canadian Cancer Society (CCS), the Canadian Institutes of Health Research - Institute of Cancer Research (CIHR-ICR), and Brain Canada Foundation for their generous financial support for Spark Grants on the Application of Disruptive Technologies in Cancer Prevention and Early Detection of the Canadian Cancer Society and the Canadian Institutes of Health Research-Institute for Cancer Research and Brain Canada Foundation (CCS grant # 707073/CIHR-IRSC grant # 0590008438). Both TMIC and BioMark will acknowledge all the supporting agencies in publications or events related to the use of the funds.

About TMIC

The Metabolomics Innovation Centre (TMIC) is a nationally funded network that offers a unique combination of infrastructure and expertise to perform a wide range of cutting-edge metabolomic studies for clinical trials research, biomedical studies, bioproducts studies, nutrient profiling and environmental testing. Network scientists include Dr. Liang Li (University of Alberta), Dr. David Wishart (University of Alberta), Dr. Christoph Borchers (McGill University), Dr. James Harynuk (University of Alberta), Dr. Michael Overduin (University of Alberta), Dr. David Goodlett (University of Victoria), Dr. Philip Britz-

McKibbin (McMaster University) and Dr. Ian Lewis (University of Calgary).

TMIC has access to more than \$26 million in state-of-the-art metabolomics infrastructure. It is supported by a team of lab managers, NMR spectroscopists, mass spectrometrists, chemists, computer scientists, statisticians and bioinformaticians. TMIC is capable of identifying and quantifying up to 2000 different chemicals from certain biological samples. This is approximately 5X more comprehensive than any other service currently available.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early and cost-effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website <https://thecse.com/>.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-370-0779

Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved the content of this press release.



To view the source version of this press release, please visit <https://www.newsfilecorp.com/release/77372>